# Outcomes After Repeat Alcohol Septal Ablation in Patients With Obstructive Hypertrophic Cardiomyopathy

**Authors:** Takashi Hiruma, Mitsunobu Kitamura, Itaru Takamisawa, Ryo Abe, Tosei Kawai, Takashi Funaki, Yuki Izumi, Ryosuke Higuchi, Junya Matsuda, Yukichi Tokita, Mamoru Nanasato, Nobuo Iguchi, Tomohiro Iwakura, Tomoki Shimokawa, Shuichiro Takanashi, Hiroo Takayama, Yuichi J. Shimada, Hitoshi Takano, Kuniya Asai, Mitsuaki Isobe, Morimasa Takayama

PMC · DOI: 10.1016/j.jacadv.2026.102595 · 2026-02-14

## TL;DR

This study examines the outcomes of repeat alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy, finding that success rates and long-term risks vary based on the location of the obstruction.

## Contribution

The study provides new insights into the effectiveness and outcomes of repeat alcohol septal ablation based on the site of residual obstruction.

## Key findings

- 80.7% of patients achieved the primary endpoint of reduced symptoms or obstruction after repeat ASA.
- Proximal obstruction was associated with better outcomes compared to distal obstruction.
- Fatal arrhythmia and third interventions were more common in patients with distal obstruction.

## Abstract

Alcohol septal ablation (ASA) may necessitate a repeat procedure if the obstructive myocardium is not sufficiently ablated; however, the outcomes after repeat ASA are not well studied.

The objective of the study was to evaluate outcomes in patients with obstructive hypertrophic cardiomyopathy after repeat ASA.

Of the 663 patients with obstructive hypertrophic cardiomyopathy who underwent ASA, 84 with repeat ASA were analyzed. Residual left ventricular (LV) obstruction was stratified according to proximal or distal obstruction. The primary outcome was the absence of symptomatic residual LV obstruction, defined as NYHA functional class I or LV gradient <50 mm Hg, or both at 12 months after repeat ASA. Factors associated with the primary outcome were assessed using logistic regression. Secondary outcomes included cardiovascular mortality, fatal arrhythmia, heart failure hospitalization, and 3rd intervention.

Of the 84 patients, 41 had proximal and 43 had distal obstruction. Five patients failed to achieve technical success. One patient with proximal obstruction died due to infection during the index hospitalization. At 12 months after repeat ASA, 80.7% (67/83) achieved the primary endpoint: 90.0% (36/40) with proximal obstruction and 72.1% (31/43) with distal obstruction. The primary outcome was associated with proximal obstruction (adjusted OR: 4.06; 95% CI: 1.09-18.3). During a median follow-up of 7.1 years, there were 13 deaths (15.5%). Cardiovascular mortality and heart failure hospitalization were similar between those with proximal or distal obstruction, whereas fatal arrhythmia and 3rd interventions were more frequent in distal obstruction.

The site of residual obstruction may be important for understanding long-term outcomes after repeat ASA, but this requires further studies.

## Linked entities

- **Diseases:** hypertrophic cardiomyopathy (MONDO:0005045)

## Full-text entities

- **Genes:** MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}
- **Diseases:** ventricular tachycardia (MESH:D017180), septic shock (MESH:D012772), ventricular fibrillation (MESH:D014693), heart failure (MESH:D006333), allergic reactions (MESH:D004342), Hypertrophic Cardiomyopathy (MESH:D002312), atrial fibrillation (MESH:D001281), hypertrophy (MESH:D006984), Cardiovascular death (MESH:D002318), infection (MESH:D007239), atrioventricular block (MESH:D054537), branch occlusion (MESH:D012170), distal septal obstruction (MESH:D024741), hypertrophied LV (MESH:D017379), death (MESH:D003643), arrhythmic (OMIM:212500), TRANSLATIONAL (OMIM:614922), obstructive (MESH:D000402), HCM (MESH:D000092183), Structural anomalies of the LV and mitral valve complex (MESH:D008944), arrhythmia (MESH:D001145), aortic stenosis (MESH:D001024), LV (MESH:D018487), stroke (MESH:D020521), sudden cardiac death (MESH:D016757), myocardial (MESH:D009202), valvular heart disease (MESH:D006349), SAM (MESH:D009041), chronic kidney disease (MESH:D051436), syncopal (MESH:D013575), ASA (MESH:D000437), LV obstruction (MESH:D000092242)
- **Chemicals:** Alcohol (MESH:D000438), ASA (-), ethanol (MESH:D000431)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12925452/full.md

---
Source: https://tomesphere.com/paper/PMC12925452